Intended for healthcare professionals

CCBYNC Open access

Rapid response to:

Research

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k119 (Published 06 February 2018) Cite this as: BMJ 2018;360:k119

Rapid Response:

Re: Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Dear Authors,

The cardiovascular endpoint is very encouraging but was the rate of UTIs, recurrent, complicated or just simple UTI measured please ? With antimicrobial stewardship being such a hot topic, presumably the infection rate needs to be known before widespread roll-out of gliflozin prescribing. UTIs are stated to be a common side-effect for all gliflozins. Reduced cardiovacsular harm but at what cost ?

Thank you

Janet Thomas (Mrs)
Patient Safety Pharmacist
Wrexham Maelor Hospital
BCUHB

Competing interests: No competing interests

05 August 2019
JANET E THOMAS
Hospital Pharmacist
BCUHB